COMPASS PATHWAYS PLC Accrued Professional Fees, Current
COMPASS PATHWAYS PLC (CMPS) had Accrued Professional Fees, Current of $1.34 million as of 2025-12-31, per its 10-K filed 2026-03-24.
Financial Statements › Notes › Payables and Accruals
us-gaap:AccruedProfessionalFeesCurrent · last filed 2026-03-24
- 2025-12-31: Accrued Professional Fees, Current $1.34M.
- 2024-12-31: Accrued Professional Fees, Current $1.53M.
- 2024-03-31: Accrued Professional Fees, Current $1.25M.
- 2023-12-31: Accrued Professional Fees, Current $1.08M.
| Period end | Accrued Professional Fees, Current |
|---|---|
| 2025-12-31 | $1.34M 10-K · filed 2026-03-24 |
| 2024-12-31 | $1.53M 10-K · filed 2026-03-24 |
| 2024-03-31 | $1.25M 10-Q · filed 2024-05-08 |
| 2023-12-31 | $1.08M 10-K · filed 2025-02-27 |
| 2023-09-30 | $1.28M 10-Q · filed 2023-11-02 |
| 2023-06-30 | $1.81M 10-Q · filed 2023-08-03 |
| 2023-03-31 | $803.00K 10-Q · filed 2023-05-11 |
| 2022-12-31 | $1.28M 10-K · filed 2024-02-29 |
| 2022-09-30 | $1.46M 10-Q · filed 2022-11-03 |
| 2022-06-30 | $1.55M 10-Q · filed 2022-08-04 |
| 2022-03-31 | $1.76M 10-Q · filed 2022-05-10 |
| 2021-12-31 | $1.39M 10-K · filed 2023-02-28 |
| 2021-09-30 | $768.00K 6-K · filed 2021-11-09 |
| 2021-06-30 | $362.00K 6-K · filed 2021-08-11 |
| 2020-12-31 | $701.00K 10-K · filed 2022-02-24 |
| 2019-12-31 | $232.00K 20-F · filed 2021-03-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ANI PHARMACEUTICALS INC (ANIP) | United States | $1.810B | 18.77 |
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |
| Xencor Inc (XNCR) | United States | $1.776B | -7.33 |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |